Dare Bioscience

Dare Bioscience R&D Expenses

The Research & Development Expenses of Dare Bioscience (DARE) as of Oct 30, 2026 is 5.52 B USD. In the previous year, Research & Development Expenses was 14.21 M USD — a change of 38,782.58% (higher).

R&D Expenses

5.52 BUSD

YoY

38,782.58%

Last updated:

Research & Development Expenses of Dare Bioscience is 2025 5.52 B USD. Research & Development Expenses of Dare Bioscience was 2024 14.21 M USD. It decreases by 38,782.58% higher compared to the previous year.

The Dare Bioscience R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2018
6.41 M USD
Jan 1, 2019
8.55 M USD
Jan 1, 2020
20.77 M USD
Jan 1, 2021
30.62 M USD
Jan 1, 2022
30.04 M USD
Jan 1, 2023
21.54 M USD
Jan 1, 2024
14.21 M USD
Jan 1, 2025
5.52 B USD
The Dare Bioscience R&D Expenses history
YEARR&D ExpensesYoY
5.52 BUSD+38,782.58%
14.21 MUSD-34.05%
21.54 MUSD-28.31%
30.04 MUSD-1.88%
30.62 MUSD+47.42%
20.77 MUSD+143.03%
8.55 MUSD+33.24%
6.41 MUSD+551.33%
984,749.00USD-96.43%
27.57 MUSD+6.23%
25.95 MUSD+120.42%
11.77 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Research & Development Expenses of Dare Bioscience is 5.52 B USD in 2025.

Research & Development Expenses of Dare Bioscience changed from 14.21 M USD to 5.52 B USD, representing a 38,782.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Dare Bioscience

All Key Metrics — Dare Bioscience